Lipid-based nanoparticles are evolving—faster, safer and more precise than ever. With traditional LNPs struggling to reach tissues beyond the liver, the industry is doubling down on next generation technologies for extra-hepatic. In 2024 alone, Novo Nordisk invested $600M in NanoVation to push genetic medicines further, while Nanite and Saliogen joined forces to pioneer non-viral, lung-targeting nanoparticles.

Formerly known as the Next Gen Lipid-Based Nanoparticle Delivery Summit, the summit is the only industry-dedicated event laser-focused on extrahepatic targeting, delivery efficiency and scalable manufacturing for mRNA, siRNA, DNA and gene therapies.

Join 80+ delivery experts, CXOs and leading scientists from AstraZeneca, Novo Nordisk, Takeda, Orbital Therapeutics and more for three jam-packed days in Boston this June. Get exclusive insights, real-world case studies and cutting-edge strategies to supercharge your lipid-based delivery vehicles beyond the liver and into the next generation.

Event link here.